Compare CVS Health Corp (CVS) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Sea Limited — how do they compare? CVS Health Corp trades at $86.2 (market cap $112.49B), while Sea Limited trades at $94.5 (market cap $57.98B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while Sea Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Sea Limited for 102 Days on average.
| CVS | SE | |
|---|---|---|
Market Cap | $112.49B | $57.98B |
Volume | 8,467,392 | 4,033,686 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $188.00 |
52-Week Low | $70.08 | $78.16 |
Typical Hold Time | 83 Days | 102 Days |
Enterprise Value | $174.83B | $53.01B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Sea Limited (SE) trades at $92.89, down 3.77% on the day, with bearish technical signals dominating despite strong fundamental growth. The company reported robust revenue growth from $22.94B in 2025 to $27.7B projected for 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 70% buy ratings and a $153.67 consensus price target representing 65% upside potential.
The investment case hinges on Sea's continued e-commerce and fintech expansion, though the stock faces near-term technical pressure. Key risks include margin compression concerns and insider selling activity. With strong cash flow generation improving from negative $3.2B in 2022 to positive $2.34B in 2025, the fundamentals support long-term growth despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
